Queue
Flozinator
Blog
PodCast
More
Club de Articulos
Code of Conduct
The Why, When and How
The NephJC Organization
Twitter Journal Club Primer
Who are we
Masthead
COVID19
Seminars in Nephrology
Regarding Twitter...
Newsletter

NephJC

Queue
Flozinator
Blog
PodCast
More
Club de Articulos
Code of Conduct
The Why, When and How
The NephJC Organization
Twitter Journal Club Primer
Who are we
Masthead
COVID19
Seminars in Nephrology
Regarding Twitter...
Newsletter
joel topf
October 27, 2015
Archive

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

joel topf
October 27, 2015
Archive

Summary | Pubmed | Storify | Symplur

Tagged: Lancet, Hypertension, Aldosterone antagonists, Crossover trial, Positive, Potassium

Newer PostA Randomized Trial of Intensive versus Standard Blood-Pressure Control
Older PostTherapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function
  • AKI 7
  • Aldosterone antagonists 1
  • Am J Respir Crit Care Med 1
  • Anemia 1
  • Annals of Internal Medicine 2
  • Anticoagulation 1
  • BMJ 1
  • Basic Science 3
  • Book Club 1
  • CJASN 3
  • CKD 9
  • Calcium 1
  • Cardiology 4
  • Cell Stem Cell 1
  • Clinical Practice Guidelines 2
  • Contrast 1
  • Critical Care (Journal) 1
  • Crossover trial 1
  • Diabetes 2
  • Diagnostics 5
  • Dialysis 1
  • Donor 1
  • ESRD 4
  • Editorial 1
  • Electrolytes 3
  • Epidemiology 2
  • Eur J Endocrinol 1
  • Fibrosis 1
  • Glomerulonephritis 1
  • Hepatology 1
  • Hyperkalemia 2
  • Hypertension 5
  • Infectious Disease 2
  • International Review of Psychiatry 1
  • Iron 1
  • J Amer Col Cards 1
  • J Clin Invest 1
  • J Nephrol 1
  • JAMA 4
  • JASN 1
  • Kidney International 2
  • Lancet 3
  • Membranous 1
  • Meta analysis 2
  • Metabolic bone disease 1
  • NDT 2
  • NEJM 7
  • Nature Reviews Nephrology 1
  • Negative 8
  • Non-drug therapy 6
Back to Top
NSMC Internship
Search
Captopril@NephJC.com